A Randomized Controlled Trial of HIV Pre-Exposure Prophylaxis Provision in the Emergency Department (PrEPPED)
Abstract
BACKGROUND
Oral human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) effectively reduces HIV transmission. However, PrEP remains underutilized due to structural, provider, and individual-level barriers, with significant disparities in access. Emergency departments (EDs) serve high-risk populations often disconnected from primary care, offering a strategic setting for initiating PrEP services. In spite of the potential, ED-based PrEP programs face challenges, and the feasibility of initiating PrEP in this setting is unclear.
OBJECTIVES
This pilot randomized controlled trial (RCT) aimed to evaluate the impact of immediate PrEP initiation (iPrEP) in the ED on PrEP usage at 90 days.
METHODS
The trial randomized eligible ED patients 1:1 to iPrEP in the ED with a 28-day starter pack given at discharge vs. referral for outpatient PrEP initiation. Participants were followed for 90 days, with the primary outcome being PrEP usage. Secondary outcomes were PrEP usage at 30 and 60 days, retention in care at 30, 60, and 90 days, HIV risk, and satisfaction.
RESULTS
Of 1455 patients screened, 169 were eligible, 27 were randomized, and 26 received their assigned intervention. At 90 days, only 3 participants were taking PrEP (2 iPrEP, 1 referral). Follow-up at 30, 60, and 90 days revealed no significant differences between the groups for any secondary outcome.
CONCLUSIONS
PrEP initiation in the ED did not improve PrEP usage or retention in care compared with referral alone.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 1,455 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.